| Ras Al Khaimah, United Arab Emirates-Tuesday, March 6th 2018 [ AETOS Wire ]
Julphar reviewed non-audited preliminary financial results for 2017 and forecasts for 2018, following its Board of Directors’ meeting, which was chaired by His Highness Sheikh Faisal Bin Saqr Al Qasimi, Chairman of the Board of Julphar.
Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, recorded sales of AED 1.3 billion for the year ending December 31, 2017, despite the challenging and rapidly changing market environment.
Julphar’s General Manager, Jerome Carle, said, “Firstly, I wish to express my gratitude to the shareholders, colleagues, customers, partners and all the stakeholders of the company for their continued support. In 2017, Julphar faced major challenges, such as currency headwinds, forex shortage, political instability and price cuts.
“However, key milestones have been achieved, including the official opening of our plant in Saudi Arabia, our entry into three highly important markets with large populations – Mexico, Uzbekistan and Sri Lanka – not to mention being ranked number one in the UAE for the first time. We also registered 130 new products last year and signed an important agreement with the Ministry of Health in the UAE to ensure the availability of critical medical supplies during crisis situations.”
“We are off to a solid start in 2018, as evidenced by the successful acquisition of Gulf Inject, new distribution agreements in Africa and Asia, all of which indicate a healthy outlook for the business. We are building up a solid pipeline and we are targeting double-digit growth in 2018 with the planned launches of 25 new products in UAE.
“We aim to increase our impact in the global pharmaceutical industry by enhancing our operations in emerging markets and increasing our presence in Africa.”
In 2017, Julphar opened a manufacturing facility in Jeddah, Saudi Arabia adding to its overseas production bases in Ethiopia and Bangladesh. The SAR 300 million state-of-the-art plant has the capacity to produce 1 billion tablets, 300 million capsules and 30 million bottles of syrups and suspensions per year.-
Earlier this month, Julphar Saudi Arabia was granted Current Good Manufacturing Practice (cGMP) approval by the Saudi Food and Drug Authority (SFDA).
About Julphar
Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, was established in 1980 under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi. The company employs 5,000 people and distributes a wide range of products to more than 50 countries on five continents across the globe.
Julphar’s business is centered on three core units – Diabetes Solutions, General Medicines, and its consumer division, Julphar Life. The company’s vast product portfolio target major therapeutic segments including Family Care, Gastrology, Pain and Wound Management, Antibiotic, Cardiovascular and Metabolism.
Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia that produce more than a million boxes of medicines a day including tablets, syrups, suspensions, creams and injectables. In 2012, Julphar became one of the largest producer of Insulin with its UAE-based Biotechnology production unit.
For more information, visit www.julphar.net.
Contacts
Julphar
Chris Goward, Head of Communications, +971582633997
chris.goward@julphar.net
Permalink : http://aetoswire.com/news/5771/en
|
